Most material SEC filings — September 2, 2026

cbdMD, Inc. (market cap ~$2.8M) entered a definitive asset purchase agreement on September 1, 2026, to acquire substantially all operating assets and brands of Twinlab Consolidated Holdings, Inc. through an assignment-for-benefit-of-creditors proceeding. Purchase price: $3,979,805 consisting of (a) assumption of $1.75M secured debt to Akretive Holdings at 9% annually, (b) issuance of 2,229,805 common shares (~19.9% of outstanding) valued at $1.00/share = $2,229,805, and (c) assumption of specified liabilities. The acquired brands include Twinlab, Reserveage, Metabolife, and Alvita Tea; combined trailing-twelve-month revenue (unaudited, through June 2026) approximately $30M, representing ~40% revenue increase for cbdMD. Transaction is subject to ABC court approval and customary closing conditions.

On August 27, 2026, Alaska Industrial Development and Export Authority (AIDEA) authorized up to $25 million in funding for geotechnical drilling, permitting, hydrologic, and engineering work on the proposed West Susitna Access Project (WSAP), a 100.5-mile public/public-private road designed to connect U.S. GoldMining's Whistler Gold-Copper Project to Anchorage-area infrastructure. This authorization covers the 2026-2027 field seasons and is critical gating work for final road design, including bridge foundation work and alignment refinement. The company's Whistler project has a preliminary economic assessment modeling $2.0B NPV5% and 33% IRR at base case prices.

uniQure announced submission of a Biologics License Application (BLA) to the FDA for ifezuntirgene inilparvovec (AMT-130) for Huntington's disease treatment, supported by three-year Phase I/II data showing slowed disease progression. The company also submitted a Marketing Authorisation Application (MAA) to the U.K. MHRA and requested priority FDA review (potential 6-month review cycle). The product holds Breakthrough Therapy, Regenerative Medicine Advanced Therapy (RMAT), and Fast Track designations from the FDA.

TScan announced a strategic reorganization: (1) pausing Phase 3 ALLOHA-2 enrollment for TSC-101 in heme malignancies due to insufficient capital after enrolling 7 patients on the treatment arm; (2) laying off ~75% of workforce; (3) shifting focus to in vivo-engineered TCR-T for solid tumors (PRAME and MAGE-A4 candidates entering IND-enabling studies with Phase 1 planned Q4 2027); (4) pursuing strategic partnerships for heme and autoimmune programs. The restructuring is expected to save $55M through end of 2027 and extend cash runway to Q4 2027. Updated Phase 1 ALLOHA data showed 100% (13/13) patients in Cohort C achieved complete donor chimerism with commercial-ready manufacturing.

G-III Apparel Group Ltd. and WHP Global completed the acquisition of Marc Jacobs brand from LVMH on September 1, 2026. The parties formed a 50-50 joint venture (MJ Topco, LLC) to co-own Marc Jacobs intellectual property, with WHP Global leading brand licensing and G-III operating the business (wholesale, retail, e-commerce). G-III targets $1 billion in long-term annual Marc Jacobs revenue; the deal is expected to be slightly dilutive in fiscal 2027 with accretion thereafter.

Edible Garden AG (market cap ~$7.7M) received formal notification from Nasdaq on September 2, 2026, confirming compliance with Listing Rule 5550(a)(2) requiring a minimum closing bid price of $1.00 per share. The company had been at risk of delisting; a Nasdaq Hearings Panel granted continued listing on July 27, 2026, conditioned on meeting this price threshold. The company now faces a one-year mandatory panel monitoring period through August 31, 2027; any future non-compliance would trigger automatic delisting without a cure period.

Rank One Computing (Nasdaq: ROC) completed its acquisition of Zuccaro Technical Consulting LLC (ZTC) on September 1, 2026. ZTC becomes a wholly owned ROC subsidiary, adding digital forensics engineering expertise, federal customer relationships, and incremental revenue. The deal expands ROC Evidence into end-to-end investigative intelligence and creates cross-selling opportunities across ROC's Vision AI portfolio. No purchase price, share count, earn-out structure, or financial metrics are disclosed in the filing.

Director Cheung Kong Yiu (NIVF) bought 3.7M shares (~$4.2M) on the open market (50% of holdings). Open-market insider purchase — historically a bullish signal.